Where will Novartis spend the $21B from Roche stake sale? Alnylam buyout could be one: report

Novartis is getting a huge influx of cash from selling its 20-year stake in Roche, triggering speculations about where the Swiss pharma will spend the money. Another large acquisition could be next, with a familiar face now reportedly on the shopping list.